HTD1801: Severe Hypertriglyceridemia (SHTG)

Hypertriglyceridemia (HTG) is a common form of a lipid disorder with a fasting plasma triglyceride (TG) above 150 mg/dL. Patients with severe hypertriglyceridemia (SHTG) have triglyceride levels more than three times the normal level,i.e. >500 mg/dL.  SHTG may result from primary (genetic defects in triglyceride metabolism) or secondary causes, including uncontrolled type 2 diabetes mellitus (T2DM), obesity, and sedentary habits. SHTG can lead to multiple serious conditions such as cardiovascular disease (CVD), acute pancreatitis and diabetic ketoacidosis.

The general treatment regimen for SHTG includes dietary restrictions and lipid-lowering  drugs such  as fibrates, omega-3-fatty acids, and nicotinic acid.  The rise in the incidence of SHTG is associated with the increasing prevalence of T2DM, therefore, a therapeutic agent that can address both T2DM and SHTG with additional beneficial effects on lipids and body weight may represent the ‘next generation’ TG lowering agent.

How HTD1801 Should Help in SHTG

Beneficial effects of HTD1801 in SHTG are expected to include:

Lowering TG as well as total cholesterol and LDL
Improved glycemic control
Weight loss

In preclinical hamster NASH/HTG model, HTD1801 significantly lowered serum triglycerides in hamsters after 6 weeks of treatment

In  NASH Phase 2a clinical trial, HTD1801 significantly lowered triglycerides and LDL-C of patients after 18 weeks of treatment

Market Overview

The total diagnosed prevalent cases of SHTG in the 7 Major Markets (7MM) including the US, Germany, France, Italy, Spain, UK and Japan are 3,465,312 in 20211. These cases are expected to increase during the forecasted period (2022–2032). Among the 7MM, the highest diagnosed prevalent cases were observed in the US and are expected to increase during the forecasted period.

The market size of SHTG in 7MM is US$3.06B in 2021, and is expected to increase at an estimated compound annual growth rate (CAGR) of 8.1% from 2019 to 2031.

Fibrates, fish oil and niacin are the main pharmacologic agents for managing SHTG, each with its own limitations.

1. DelveInsight: Severe Hypertriglyceridemia (SHTG) - Epidemiology Forecast 2032 MAR2022; 7MM = US, UK, Germany, France, Spain, Italy, Japan


We will contact you as soon as possible

© 2020 HighTide Therapeutics Inc.

Legal StatementPrivacy PolicyCookie Policy


Follow Us

© 2020 HighTide Therapeutics Inc.